Skip to main content

Table 1 Baseline characteristics of patients

From: Post-transplant cyclophosphamide versus antithymocyte globulin in patients with acute myeloid leukemia in first complete remission undergoing allogeneic stem cell transplantation from 10/10 HLA-matched unrelated donors

N

ATG

PTCY

Test p value

1452

174

 

Follow-up

 Median time (IQR) mo

33.2 (17.6–52.7)

20.5 (6.9–32.6)

< 0.001

Age at allo-HSCT

 Median (range) [IQR]

56 (18.1–77.5) [44.3–62.6]

46 (18–74.2) [34.7–59.3]

< 0.001

Year allo-HSCT

 Median (range) [IQR]

2014 (2010–2017)

2016 (2010–2017)

< 0.001

Time diagnosis to allo-HSCT

 Median (range) [IQR]

5.4 (1.5–17.7) [4.4–6.6]

4.7 (1.8–17.9) [3.8–7.7]

0.1

AML

 De novo

1206 (83.06%)

161 (92.53%)

0.001

 secAML

246 (16.94%)

13 (7.47%)

Cytogenetics (MRC)

 Good

59 (4.06%)

4 (2.3%)

0.19

 Interm

740 (50.96%)

80 (45.98%)

 Poor

291 (20.04%)

35 (20.11%)

 NA/failed

362 (24.93%)

55 (31.61%)

Conditioning regimen

 MAC

687 (47.31%)

76 (43.68%)

0.36

 RIC

765 (52.69%)

98 (56.32%)

Gaft cell type

 BM

143 (9.85%)

18 (10.34%)

0.84

 PBSC

1309 (90.15%)

156 (89.66%)

Kanofsky performance score

 < 90

331 (24.68%)

29 (16.76%)

0.02

 ≥ 90

1010 (75.32%)

144 (83.24%)

 Missing

111

1

Patient sex

 Male

759 (52.27%)

98 (56.32%)

0.31

 Female

693 (47.73%)

76 (43.68%)

Female donor-male recipient

165 (11.41%)

26 (14.94%)

0.17

Patient CMV serostatus

 Negative

499 (34.92%)

43 (25.15%)

0.011

 Positive

930 (65.08%)

128 (74.85%)

 Missing

23

3

Engraftement

 Graft failure

12 (0.83%)

2 (1.16%)

0.65

 Engrafted

1432 (99.17%)

170 (98.84%)

 Missing

8

2

  1. Abbreviations: allo-HSCT allogeneic stem cell transplantation, AML acute myeloid leukemia, ATG anti-thymocyte globulin, BM bone marrow, CMV cytomegalovirus, Interm intermediary, IQR interquartile range, KPS Karnovsky Performance Status, MAC myeloablative conditioning regimen, PBSC peripheral blood stem cell, PTCY posttransplantation cyclophosphamide, RIC reduced intensity conditioning regimen, secAML secondary acute myeloid leukemia